Alwin Krämer

Alwin Krämer


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2010 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BLBlanka Leber
Blanka Leber
BMBettina Maier
Bettina Maier
FFFlorian Fuchs
Florian Fuchs
JCJing Chi
Jing Chi
PRPhillip Riffel
Phillip Riffel
AKAlwin Krämer
Alwin Krämer
Identified in an RNA interference screen, proteins that prevent spindle multipolarity in human cancer cells may prove to be promising drug targets.

24 March 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
ABAnna L. Brown
Anna L. Brown
PAPeer Arts
Peer Arts
CCCatherine L. Carmichael
Catherine L. Carmichael
MBMilena Babic
Milena Babic
JDJulia Dobbins
Julia Dobbins
HSHamish S Scott
Hamish S Scott
First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic mutations detected in 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families detected 2 partial gene deletions, 3 novel mutations, and 5 recurrent mutations as the germline RUNX1 alterations leading to FPD-MM. Combining genomic data from the families reported herein with aggregated published data sets resulted in 130 germline RUNX1 families, which allowed us to investigate whether specific germline mutation characteristics (type, location) could explain the large phenotypic heterogeneity between patients with familial platelet disorder and different HMs. Comparing the somatic mutational signatures between the available familial (n = 35) and published sporadic (n = 137) RUNX1-mutated AML patients showed enrichment for somatic mutations affecting the second RUNX1 allele and GATA2. Conversely, we observed a decreased number of somatic mutations affecting NRAS, SRSF2, and DNMT3A and the collective genes associated with CHIP and epigenetic regulation. This is the largest aggregation and analysis of germline RUNX1 mutations performed to date, providing a unique opportunity to examine the factors underlying phenotypic differences and disease progression from FPD to MM.

13 August 2020 in Blood
Verified
Journal Article
Closed access
PDF file
CRChristoph Röllig
Christoph Röllig
MKMichael Kramer
Michael Kramer
CSChristoph Schliemann
Christoph Schliemann
JMJan-Henrik Mikesch
Jan-Henrik Mikesch
BSBjoern Steffen
Bjoern Steffen
MBMartin Bornhäuser
Martin Bornhäuser
In fit patients with newly diagnosed acute myeloid leukemia (AML), immediate treatment start is recommended due to the poor prognosis of untreated acute leukemia. We explored the relationship between time from diagnosis to treatment start (TDT) and prognosis in a large real-world data set from the German Study Alliance Leukemia–Acute Myeloid Leukemia (SAL-AML) registry. All registered non–acute promyelocytic leukemia patients with intensive induction treatment and a minimum 12 months of follow-up were selected (n = 2263). We analyzed influence of TDT on remission, early death, and overall survival (OS) in univariable analyses for each day of treatment delay, in groups of 0 to 5, 6 to 10, 11 to 15, and >15 days of TDT, adjusted for influence of established prognostic variables on outcomes. Median TDT was 3 days (interquartile range, 2-7). Unadjusted 2-year OS rates, stratified by TDT of 0 to 5, 6 to 10, 11 to 15, and >15 days, were 51%, 48%, 44%, and 50% (P = .211). In multivariable Cox regression analysis accounting for established prognostic variables, the TDT hazard ratio as a continuous variable was 1.00 (P = .617). In OS analyses, separately stratified for age ≤60 and >60 years and for high vs lower initial white blood cell count, no significant differences between TDT groups were observed. Our study suggests that TDT is not related to survival. As stratification in intensive first-line AML treatment evolves, TDT data suggest that it may be a feasible approach to wait for genetic and other laboratory test results so that clinically stable patients are assigned the best available treatment option. This trial was registered at www.clinicaltrials.gov as #NCT03188874.

19 May 2011 in Molecular Oncology
Verified
Journal Article
Closed access
AKAlwin Krämer
Alwin Krämer
BMBettina Maier
Bettina Maier
JBJiri Bartek
Jiri Bartek

31 January 2017 in Leukemia
Verified
Journal Article
Closed access
PDF file
ACA Chaturvedi
A Chaturvedi
LHL Herbst
L Herbst
Stefan PuschStefan Pusch
Stefan Pusch
LKL Klett
L Klett
RGR Goparaju
R Goparaju
AKAlwin Krämer
Alwin Krämer

22 June 2009 in Journal of Cell Biology
Verified
Journal Article
Open access
ATAlexandra Tibelius
Alexandra Tibelius
JMJoachim Marhold
Joachim Marhold
HZHanswalter Zentgraf
Hanswalter Zentgraf
CHChristoph E. Heilig
Christoph E. Heilig
HNHeidemarie Neitzel
Heidemarie Neitzel
AKAlwin Krämer
Alwin Krämer
Primary microcephaly, Seckel syndrome, and microcephalic osteodysplastic primordial dwarfism type II (MOPD II) are disorders exhibiting marked microcephaly, with small brain sizes reflecting reduced neuron production during fetal life. Although primary microcephaly can be caused by mutations in microcephalin (MCPH1), cells from patients with Seckel syndrome and MOPD II harbor mutations in ataxia telangiectasia and Rad3 related (ATR) or pericentrin (PCNT), leading to disturbed ATR signaling. In this study, we show that a lack of MCPH1 or PCNT results in a loss of Chk1 from centrosomes with subsequently deregulated activation of centrosomal cyclin B–Cdk1.